Low GSK-3β immunoreactivity in postmortem frontal cortex of schizophrenic patients
Low GSK-3β immunoreactivity in postmortem frontal cortex of schizophrenic patients
复制标题
DOI：
10.1176/appi.ajp.157.5.831
复制
发表时间：
2000-05-01
影响因子：
17.7
通讯作者：
Agam, G
中科院分区：
文献类型：
--
作者：
Kozlovsky, N;Belmaker, RH;Agam, G
目的：糖原合成酶激酶-3 （GSK-3）是一种在大脑中含量丰富的蛋白激酶。它参与了多个细胞过程的信号转导级联，特别是神经发育。为了探索GSK-3 β可能与精神疾病有关，作者检查了死后脑组织中的GSK-3 β水平。方法：采用Western blot方法测定14例精神分裂症患者、15例双相情感障碍患者、15例单相抑郁症患者和14例正常对照者额叶皮层GSK-3 β水平。结果：精神分裂症患者血清GSK-3 β水平比对照组高41%。其他诊断组与对照组没有差异。结论：这些结果与精神分裂症涉及神经发育病理学的观点一致。精神分裂症患者额叶皮层中GSK-3 β的活性部分或其活性是否也较低，以及这是否也反映在大脑的其他区域，还有待研究。
Objective: Glycogen synthase kinase-3 (GSK-3) is a protein kinase that is highly abundant in the brain. It is involved in signal transduction cascades of multiple cellular processes, particularly neurodevelopment. In an attempt to explore possible involvement of GSK-3 beta in psychiatric disorders, the authors examined its levels in postmortem brain tissue.Method: Western blot analysis was performed to measure GSK-3 beta in the frontal cortex of 14 schizophrenic patients, 15 patients with bipolar disorder, 15 patients with unipolar depression, and 14 normal comparison subjects.Results: GSK-3 beta levels were 41% tower in the schizophrenic patients than in the comparison subjects. Other diagnostic groups did not differ from the com parison subjects.Conclusions: These resuits a re consistent with the notion that schizophrenia involves neurodevelopmental pathology. It remains to be investigated whether the active fraction of GSK-3 beta, or its activity is also low in frontal cortex of schizophrenic patients and if this is also reflected in other brain regions.